Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent PE · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in recurrent PEa compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent VTEc · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in recurrent VTEc compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
DVTd · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in DVTd compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Short‐term all‐cause mortality · people with low‐risk acute pulmonary embolism
2 findings from 1 review
Long‐term all‐cause mortality · people with low‐risk acute pulmonary embolism
Outpatient showed no clear difference in long‐term all‐cause mortality compared with inpatient treatment (low certainty).
1 finding from 1 review
Major bleeding · people with low‐risk acute pulmonary embolism
Outpatient showed no clear difference in major bleeding compared with inpatient treatment (low certainty).
2 findings from 1 review
Minor bleeding · people with low‐risk acute pulmonary embolism
Outpatient showed no clear difference in minor bleeding compared with inpatient treatment (low certainty).
1 finding from 1 review
Recurrent PE · people with low‐risk acute pulmonary embolism
Outpatient may leads to higher recurrent PE compared with inpatient treatment (low certainty).
1 finding from 1 review
30‐Day amputation‐free survival · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Amputation · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
30‐Day mortality · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Vessel patency (up to 30 days) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Duration of thrombolysis (to end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Stroke · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Major bleeding · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE
1 finding from 1 review
All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review
Treatment‐associated major haemorrhage ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Treatment‐associated minor haemorrhage ( · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes treatment‐associated minor haemorrhage ( compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review